Introduction
============

As medical knowledge evolved, the general awareness of the hepatitis C virus (HCV) has changed since its discovery, as it was not only considered as the etiological cause of chronic hepatitis, but also the cause of numerous HCV-associated diseases, particularly autoimmune diseases, such as cryoglobulinemia, Sjörgen\'s syndrome and arthritis ([@b1-etm-0-0-4671]). After HCV-associated cryoglobulinemia was reported for the first time, medical research has focused on it. In the past decade, numerous studies reported that a majority of cases of mixed cryoglobulinemia (MC) were associated with HCV ([@b2-etm-0-0-4671]). Although the underlying mechanisms have not been fully clarified, cryoglobulin formation is at least linked to chronic HCV infection ([@b3-etm-0-0-4671]). A total of 20--30% of MC patients had renal involvement, mainly due to membranoproliferative glomerulonephritis (MPGN) ([@b4-etm-0-0-4671]). Therefore, treatments of these patients have mainly focused on the reduction of the viral load, the elimination of immune complexes and the function of B cells. Hence, the present case study presented a case diagnosed as MC with MPGN and its treatment, and summarized the diagnosis, clinical manifestations and treatments of MC with a particular focus on MC-associated renal injury.

Case report
===========

Informed consent was provided by the patient\'s husband for her inclusion in the present study. A-58-year-old woman presented at the Department of Nephrology of the Second Hospital of Jilin University (Changchun, China) on December 17th 2012 with intermittent edema in the lower limbs that had persisted for eight months and proteinuria for one month, while purpura on the bilateral lower limbs had been present for five years ([Fig. 1](#f1-etm-0-0-4671){ref-type="fig"}), which deteriorated in the cold. The patient\'s clinical and laboratory data at first presentation are listed in [Table I](#tI-etm-0-0-4671){ref-type="table"}. The qualitative cryoglobulin test was positive. Renal biopsy was performed and immunofluorescence results were as follows: Immunoglobulin (Ig)A(+/−), IgM(+), IgG(+), complement C3(2+), complement C4(−), complement factor lq(+) and fibrinogen(−). Light microscopic: Periodic Acid-Schiff staining revealed 37 intact glomeruli, parts of which were hypertrophic, and two sclerotic gomeruli, one of which displayed fibrous crescent formation. Glomerular mesangial cells and endothelial cells were diffuse with severe hyperplasia. Vacuolar degeneration of endothelial cells and microthrombosis in capillary lumens was observed, and most of the capillary loops were obstructed. Various renal tubular epithelial cells had degenerated with small focal atrophy and occasional protein casts. Renal interstitial edema, focal inflammation and inflammatory cell infiltration were present, particularly around blood vessels. Part of the wall of an arteriole was slightly thickened; Periodic Acid Methenamine Silver + Masson staining revealed a diffuse double track appearance without identifiable spikes, and endothelial and mesangial areas contained diffuse eosinophilic complexes with red staining ([Fig. 2](#f2-etm-0-0-4671){ref-type="fig"}). The pathological diagnosis was mesangial proliferative glomerulonephritis (HCV-associated cryoglobulinemia) with a possibility of MPGN. Based on all of these results and the quantity of HCV RNA, the patient was given interferon α (500,000 IU every other day) by subcutaneous injection from December 19th 2012 until the quantity of HCV RNA reached below the minimum on January 30th 2013. Subsequently, the patient was treated with prednisolone (40 mg daily) and continued to use interferon α. In response to this treatment, the results of continuous examinations of the liver, kidney function, blood, routine urine, 24-h proteinuria and the load of HCV RNA remained steady. The patient\'s 24-h proteinuria was reduced to 1.95 g after three months and continued to take oral prednisolone and interferon α without the occurrence of any edema. Therefore, prednisolone was gradually reduced, while interferon α treatment was continued.

The patient presented at our department for the second time on August 30th 2013 due to elevated axillary temperature (\>37.2°C) for 15 days and after using interferon α; further symptoms, including cough, expectoration, abdominal pain, diarrhea as well as increased urinary frequency and urgency, were not present. Clinical examination revealed an axillary temperature of 38°C and a blood pressure of 160/80 mmHg, and findings of the heart, lung and abdominal examination were unremarkable. The bilateral lower limbs showed a large tract of purpura without tenderness and edema. Laboratory parameters were as follows (normal ranges in brackets): Albumin (40--55 g/l), 40.2 g/l; creatinine (44--106 µmol/l), 81.8 µmol/l; blood leukocytes (3.5--9.510^9^ cells/l), 18.3×10^9^ cells/l; hemoglobin (115--150 g/l), 108 g/l; platelets (125--350×10^9^ cells/l), 154×10^9^ cells/l; urine protein (negative), 2+; urine leucocytes \[0-5/high power field (HPF)\], 81.3/HPF. Chest computed tomography showed tracheitis. Abdominal doppler ultrasound was normal. The load of HCV was always below the minimum value. These results were unlikely to be due to prednisolone intake, while the use of interferon α may have caused the fever; it was therefore discontinued and anti-inflammatory therapy (linezolid, 0.6 g twice daily; meropenem, 1.0 g twice daily; and micafungin, 0.15 g once daily, all intravenous) was commenced. The temperature was consistently \>39°C and returned to normal values after 2 days. However, the whole blood cell count decreased significantly, while serum creatinine increased and oliguria occurred, and the patient died of multiple organ dysfunction syndrome on November 22nd 2013.

Discussion
==========

MC-associated glomerulonephritis is the most important extrahepatic manifestation of chronic HCV infection, but its prognosis is poor. Furthermore, as unified treatment guidelines are currently lacking, a comprehensive and rigorous assessment of each patient is required, based on which a reasonable treatment is selected and changes of the disease require monitoring, particularly when various drugs are used in combination.

HCV has been considered as the major etiological cause of non-A and -B chronic hepatitis since its discovery in 1989; furthermore, clinical and experimental studies showed that HCV may cause certain autoimmune diseases, such as MC and Sjörgen\'s syndrome ([@b1-etm-0-0-4671]). While it has been reported that \~1/3 of HCV-associated MC was accompanied with renal damage ([@b5-etm-0-0-4671]), this rarely occurs in China, only few case reports ([@b6-etm-0-0-4671]). Tarantino *et al* ([@b7-etm-0-0-4671]) postulated the following major clinical diagnostic criteria: i) Cryoglobulin present in serum; ii) hematuria, proteinuria and renal damage; and iii) renal biopsy pathology consistent with the pathological characteristics of cryoglobulinemia nephropathy. Other minor clinical features such as purpura and rheumatoid factor may also be considered. The quantitative determination of cryoglobuline is of high importance. However, due to the limitations of our hospital, only qualitative detection was possible. Combined with the pathological results, clinical manifestations and auxiliary examination, the diagnosis of cryoglobulinemia was established.

As cryolobulinemia is vasculitis in its essence, it may involve multiple organs. The deposition of cryoglobulins and complement leads to diverse pathological manifestations, including purpura, skin ulcers and glomerulonephritis. The most common symptoms of MC are weakness, peripheral neuropathy, arthralgias and purpura (Meltzer and Franklin triad), Raynaud\'s phenomenon, sicca syndrome, renal involvement, lung disorders, elevated axillary temperature \>37.2°C and hematocytopenia. The frequent manifestations of MC are peripheral neuropathy and skin ulcers, which are barely responsive to treatments and may consequently compromise the patient\'s quality of life. The association between cryoglobulinemia and glomerulonephritis has been demonstrated ([@b8-etm-0-0-4671]). In previous studies, 20% of patients with MC were diagnosed with nephropathy, which even increased to 35--60% during the follow-up period, and renal injury is one of the factors associated with the worst prognosis of MC patients ([@b8-etm-0-0-4671],[@b9-etm-0-0-4671]). MC-associated nephropathy is clinically characterized by hematuria, proteinuria, edema and renal failure. The pathology is similar to MPGN, but histological examination of renal biopsy specimens revealed cryoglobulin thrombi in the capillaries. Clinical studies have shown that MC patients often present with one or more subclinical signs of renal involvement, including asymptomatic hematuria, nephrotic syndrome, nephrotic proteinuria (\<3 g/24 h), or only renal dysfunction ([@b10-etm-0-0-4671]). A total of 30% of patients may present with acute nephrotic syndrome ([@b11-etm-0-0-4671]). Nearly 15% of patients progressed to terminal chronic renal failure, even requiring dialysis ([@b12-etm-0-0-4671]). Certain examinations are important; the obvious reduction or undetectable levels of complement C4 are another hallmark of the disease and is particularly useful for disease classification, while the activity/severity of cryoglobulinemia is rarely correlated with the complement C4 level. However, they are not appropriate for clinical monitoring of patients and therapeutic decision-making.

The treatment of HCV-associated MC is particularly based on the complex pathogeny and clinical manifestations of the disease. In fact, MC may be treated at three different levels; type I cryoglobulinemia, type II cryoglobulinemia and type III cryoglobulinemia. The principles for treating MC are as follows: i) If no symptoms of cryoglobulinemia are present, no treatment is applied; ii) secondary cryoglobulinemia is mainly managed by treating the primary disease; iii) if only joint symptoms are present, non-steroid anti-inflammatory drugs are given; iv) corticosteroids and immunosuppressive agents are suitable for patients with serious illness and visceral injury; and v) plasma exchange for severe disease ([@b13-etm-0-0-4671]). Studies have suggested that low doses of interleukin 2 are suitable for treating HCV-associated cryoglobulinemia. The treatment of HCV infection-associated symptoms mainly comprises anti-viral therapy, but guidelines regarding the best anti-viral treatment of these patients remain to be established. The current options are pegylated interferon α and ribavirin, which are applied according to the type and the quantity of HCV. Thus, rituximab has been used as an agent to treat HCV-associated autoimmune diseases according to B-cell lymphoproliferation ([@b14-etm-0-0-4671]--[@b16-etm-0-0-4671]). The patient of the present study was a typical case of cryoglobulinemia and renal damage secondary to HCV infection; prednisolone combined with interferon therapy was initially effective, while multiple organ failure and death eventually occurred. As cryoglobulinemia is essentially vasculitis, it ultimately causes multiple organ damage, and the prognosis of patients with renal damage caused by HCV is therefore poor. Despite of the early treatment with prednisolone and interferon being effective, it easily induces refractory infections.

In conclusion, the present study found that HCV-associated cryoglobulinemia with MPGN treated with prednisolone and interferon α is effective; however, monitoring of the patient focused on the drugs\' effects, while side effects wereignored. Therefore, the present case study provided experience for future treatments and it is suggested that clinical studies are required to identify the most appropriate treatment strategies.
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Laboratory parameters at onset.

  Parameter                             Value        Normal range
  ------------------------------------- ------------ --------------
  White blood cells (×10^9^/l)          6.7          3.5--9.5
  Haemoglobin (g/l)                     93           115--150
  Platelet count (×109/l)               207          125--350
  Creatinine (µmol/l)                   76.9         44--106
  Proteinuria/24 h (g)                  3.65         \<0.15
  Albumin (g/l)                         22.5         40--55
  HBsAg                                 Negative     0--0.05
  Anti-HBs                              Negative     Negative
  Anti-HBc                              Negative     Negative
  HCV-RNA (IU/ml)                       1.12×10^7^   \<1.0e2
  Rheumatoid factor (IU/ml)             459.0        \<20
  Complement C4 (mg/dl)                 \<1.67       16--38
  Complement C3 (mg/dl)                 91.6         79--152
  ANA                                   Negative     \<1:100
  HIV                                   Negative     0--1.0
  Proteinuria                           3+           Negative
  IgG (g/l)                             10.7         7.51--15.6
  IgM (g/l)                             3.4          0.46--3.04
  IgA (g/l)                             1.85         0.82--4.53
  Erythrocyte sedimentation rate (mm)   74.0         \<20
  ANCA                                  Negative     Negative

Ig, immunoglobulin; HBsAg, hepatitis B surface antigen; HIV, human immunodeficiency virus; ANA, antinuclear antibody; HCV, hepatitis C virus; ANCA, antineutrophil cytoplasmic antibodies.
